Medixon

Severe hypersensitivity & dermatological reactions; severe acute & chronic inflammatory & allergic eye processes; status asthmaticus; suppression of graft rejection reactions; cerebral edema; GI diseases; fulminating SLE; shock unresponsive to conventional therapy; rheumatic disorders. Short-term adjuvant treatment in acute phase or exacerbation of post-traumatic & synovitis OA. Acute & subacute bursitis, epicondylitis, acute non-specific tenosynovitis & gouty arthritis, spondylitis ankylopoetica. TB meningitis.

Adult Graft rejection reactions 1 g daily. Acute rejection 500 mg-1 g. Status asthmaticus 40 mg IV. Pre-op edema due to brain tumor 20 mg IM 3-6 hrly or 40 mg IM 6 hrly for 2-3 days. During surgery of edema due to brain tumor 20-40 mg IV hrly. Post-op edema due to brain tumor 8, 12, 16 or 20 mg IM 3 hrly for 24 hr. Acute exacerbations of multiple sclerosis 1,000 mg daily for 3 days. Other indications Initially 10-500 mg. Childn Hematological, rheumatic, renal & dermatological conditions 30 mg/kg daily to max: 1 g daily. Graft rejection reactions 10-20 mg/kg daily for 3 days to max: 1 g daily. Status asthmaticus 1-4 mg/kg daily for 1-3 days.

Hypersensitivity. Systemic fungal infections, cerebral edema in malaria. Concomitant use w/ live or live, attenuated vaccines. Intrathecal use.

Anaphylactic/anaphylactoid reactions. Not to be used for septic syndrome or shock & management of head injury or stroke. Avoid use in patients w/ Cushing's disease; exposure to measles or close personal contact w/ chickenpox or herpes zoster. Immunosuppressant effects/increased susceptibility to infections, parasitic infections, impaired immune responsiveness, latent TB or tuberculin reactivity, Kaposi's sarcoma; hypothalamic-pituitary-adrenal suppression; unusual stress; hypothyroidism; DM; existing or previous history of severe affective disorders; seizure disorders, epilepsy, myasthenia gravis, osteoporosis; glaucoma, ocular herpes simplex; existing CV risk factors, CHF, recent MI; HTN; ulcerative colitis, perforation, abscess or other pyogenic infections, diverticulitis, fresh intestinal anastomoses, peptic ulceration; acute pancreatitis; pheochromocytoma crisis. May lead to menstrual irregularities. Dietary salt restriction & K supplement. High-dose & long-term use. Avoid abrupt w/drawal. Concomitant use w/ aspirin, NSAIDs, cardioactive drugs eg, digoxin. Renal insufficiency. Pregnancy & lactation. Not to be used in neonates. Avoid use in childn <2 yr. Monitor growth & development in infants & childn. Elderly.

Infection; Cushingoid; Na & fluid retention; psychiatric reactions ie, affective disorders, psychotic reactions, behavioral & sleep disturbances, irritability, anxiety, cognitive dysfunction ie, confusion & amnesia; posterior subcapsular cataracts; HTN; peptic ulcer; peripheral edema, ecchymosis, skin atrophy, acne; growth retardation in childn, osteoporosis, muscular weakness; impaired wound healing; decreased blood K.

Increased plasma conc by troleandomycin, INH, grapefruit juice. Decreased plasma conc by rifampin, phenobarb, phenytoin. Inhibited/induced hepatic clearance w/ aprepitant, fosaprepitant, itraconazole, ketoconazole, HIV-PIs, diltiazem, OCs, carbamazepine, cyclophosphamide, tacrolimus. Mutual inhibition of metabolism w/ ciclosporin, clarithromycin, erythromycin. Enhanced/diminished effects w/ anticoagulants. Antagonized pancuronium & vecuronium neuromuscular blocking effects. Increased blood glucose conc. Aminoglutethimide-induced adrenal suppression may impede endocrine changes. Increased incidence of GI bleeding & ulceration w/ NSAIDs. Increased high-dose aspirin clearance. Development of hypokalemia w/ K-depleting agents. Antagonized diuretic & hypotensive effects. Increased risk of hypokalemia w/ cardiac glycosides. Reduced effect by mifepristone. Incompatibility w/ aminophylline, benzylpenicillin, Ca gluconate, ciprofloxacin, cisatracurium, dolasetron, filgrastim, glycopyrrolate, soluble insulin, metaraminol, ondansetron, pantoprazole, KCl, propofol, rocuronium, tigecycline.

Corticosteroid Hormones

H02AB04 - methylprednisolone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.

B